OSSM-007 is under clinical development by Ossium Health and currently in Phase I for Asthma. According to GlobalData, Phase I drugs for Asthma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OSSM-007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OSSM-007 overview

OSSM-007 is under investigation for the prophylaxis of  asthma. It is administered through parenteral route. The therapeutic candidate comprises of interferon gamma (IFNg)-primed human bone marrow-derived mesenchymal stromal cells. It was also under development for acute graft versus host disease.

Ossium Health overview

Ossium Health is a bone marrow bank to treat blood cancers, improve organ transplantation, and repair damage from radiation that develops and manufactures cell therapy products that cure leukemia and other blood cancers, improve organ transplantation, treat radiation poisoning, and heal tissue damage. Ossium Health is headquartered in San Francisco, California, the US.

For a complete picture of OSSM-007’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.